Hepatitis C virus treatment as prevention in people who inject drugs

Hepatitis C virus vaccines among people who inject drugs.

Most people who inject drugs (PWID) are infected with hepatitis C virus (HCV), and PWID have the highest risk of HCV infection of any risk group. The incidence of HCV infection is 5%-25% per year, demonstrating continued need for HCV infection prevention in PWID. Existing data in chimpanzees and PWID suggest that protective immunity against persistent HCV infection is achievable. Due to the hig...

Impact of a treatment as prevention strategy on hepatitis C virus transmission and on morbidity in people who inject drugs

Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy)are becoming

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

The demonstration that antiretroviral treatment is effective for the prevention of human immunodeficiency virus (HIV) transmission has important implications for HCV prevention. HCV therapeutic development is advancing rapidly, with effective, simplified regimens available in the near future. In contrast to HIV, HCV treatment is both curative and circumscribed in duration-2 features that hold g...

to new hepatitis C therapies for people who inject drugs

Treatment as prevention: the breaking of taboos is required in the fight against hepatitis C among people who inject drugs.

H igh prevalence and incidence rates contrast starkly with low detection and treatment uptake rates and that makes the hepatitis C epidemic among people who inject drugs (PWID) a serious public health issue. In expectance of new interferon (IFN)-free hepatitis C treatment regimens, Martin et al. present, in this issue of HEPATOLOGY, mathematical model calculations on an approach that is already...